Tag Archives: Diagnovus

January 2014—Diagnovus announced an addition to its Engauge cancer assay portfolio with the launch of the Engauge-cancer DLBCL Gene Panel, a genomic profile to aid physicians in tailoring treatment specifically for patients with diffuse large B-cell lymphoma.

Diagnovus, a molecular diagnostics company focused on underserved, aggressive, and lesser-known diseases, announced the launch of the Engauge GI Barrett’s Esophagus genomic assay to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett’s esophagus patients.

Diagnovus has launched Engauge-cancer-DLBCL, a commercial gene-expression assay for risk stratification and treatment of patients with diffuse large B-cell lymphoma. “Engauge-cancer-DLBCL, which combines a patient’s IPI [International Prognostic Index] score and the results of the gene-expression assay, can more accurately predict outcomes for patients than IPI alone in order to optimize treatment choices for patients,” Ron Levy, MD, leader of the Lymphoma Program at Stanford University School of Medicine, said in a statement.